Acelyrin Stock

acelyrin.comHealthcare / BioTech & PharmaFounded: 2020Funding to Date: $558MM

Acelyrin is a biopharma company that invests in, develops and commercializes life-changing innovative therapeutics and transformative medicines. Acelyrin partners with big pharmaceutical companies, early-stage startups, and academia with a blend of scientific, medical, operational, and company-building experience to bring its treatments and therapeutics to the public, and transform patient's lives through healing and wellbeing.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to Acelyrin before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value

Powered by Forge Data

Access valuation and stock price for companies like Acelyrin before its IPO.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Acelyrin’s stock FAQs


Can you buy Acelyrin’s stock?

You can no longer buy Acelyrin’s stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.

Can you sell Acelyrin’s stock?

You can no longer sell stock of Acelyrin on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.

What is Acelyrin’s stock price?

The stock price of Acelyrin is $5.97 as of 1/18/24.

What is Acelyrin’s stock ticker symbol?

The ticker symbol of Acelyrin is SLRN.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.


Management Team

Shao-Lee Lin, MD, PhD
Chief Executive Officer
Robert F. Carey
Paul Peloso
Chief Medical Officer
Melanie Gloria
Chief Operating Officer
Gil Labrucherie
Chief Financial Officer
Ron Oyston
Senior Vice President, Human Resources
Marc Kubasak
Vice President, Program Lead & Regulatory Affairs
Brian Wiens
Vice President, Biostatistics and Data Sciences
Terry Bevirt
Vice President, Alliance Management, Clinical & Corporate Quality
Katherine To
Vice President - Clinical Operations
Suzy Buckhalter
Senior Director, Finance & Accounting
Tyler Marciniak
Head of Investor Relations and Communications
Shawn Eisnberg
Vice President, Technical Operations

Board Members

Sean Harper
Kin Insurance
Alan Colowick
Sofinnova Investments
Beth Seidenberg
Westlake Village BioPartners
Dan Becker
Access Biotechnology
Richard Gaster
venBio Partners


Immunology-Drug Startup Acelyrin Raises $300 Million for Late-Stage Trials

Drugmaker Acelyrin has raised $300 million in new venture capital to run late-stage clinical trials of a drug that could treat certain forms of arthritis and other conditions and compete with top-selling medications.
Updated on: Jul 12, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.